13 May 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
CEO Interview: Advancing Thalia's RNA Therapeutics Strategy
Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon.
In the interview, Dr Solomon discusses the Company's strategic transition to Thalia Therapeutics, the rationale behind its increasing focus on high-value RNA therapeutics, the continued development of Nuvec®, and the opportunities the Company sees in cardiovascular disease and oncology.
The interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates
- Ends -
For more information please contact:
|
Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer |
Via Thalia Investor Hub |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang |
Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
About Thalia Therapeutics plc
Thalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to enable oral delivery, avoidance of unwanted immune responses, and excellent stability and storage.
For further information visit www.thaliatx.com